B·R·A·H·M·S Oncology Biomarkers

A broad range of tumour markers to help manage patients with cancer

Explore B·R·A·H·M·S for oncology

Trusted assays for cancer detection and diagnosis

B·R·A·H·M·S provides a diverse range of tumour markers to detect and diagnose cancers. Tumour markers are substances produced by cancer or by other cells of the body in response to cancer and can be found in bodily fluids such as blood.

 

Since 1970, the survival rate of cancer patients has improved considerably due to earlier detection and diagnosis – and biomarkers have played a significant role in this clinical capability. Tumour markers may suggest the presence of a cancer and are typically measured before and during cancer therapy to monitor how levels change.

  Informational: This product is not available for purchase by the general public

B·R·A·H·M·S oncology biomarkers

The B·R·A·H·M·S oncology biomarkers include the following: 

  • B·R·A·H·M·S CgA II KRYPTOR (Chromogranin A) for therapy monitoring of neuroendocrine tumours and prostate cancer
  • B·R·A·H·M·S AFP KRYPTOR in liver cell carcinoma and testicular tumours
  • B·R·A·H·M·S CA 125 II KRYPTOR in ovarian cancer
  • B·R·A·H·M·S CA 15-3 KRYPTOR in breast cancer
  • B·R·A·H·M·S CA 19-9 KRYPTOR in pancreatic and colon cancer
  • B·R·A·H·M·S CEA KRYPTOR in colon cancer
  • B·R·A·H·M·S CYFRA 21-1 KRYPTOR in non-small cell lung cancer (NSCLC)
  • B·R·A·H·M·S NSE KRYPTOR in small cell lung cancer (SCLC)
  • B·R·A·H·M·S Total PSA KRYPTOR or B·R·A·H·M·S Total PSA KRYPTOR in prostate cancer
  • B·R·A·H·M·S SCC KRYPTOR in cervical cancer and non-small cell lung cancer (NSCLC)
  • B·R·A·H·M·S Tg assays and B·R·A·H·M·S Calcitonin RIA in thyroid carcinoma

Therapy monitoring of neuroendocrine tumours and prostate cancer

CgA II KRYPTOR (Chromogranin A)

Even though elevated tumour marker levels may suggest the presence of cancer, the marker is usually combined with other clinical findings for cancer diagnosis. This is the reason why tumour markers are typically measured before and during cancer therapy to monitor how levels change. B·R·A·H·M·S CgA II KRYPTOR is a fully automated assay measured on the B·R·A·H·M·S KRYPTOR laboratory platform.

 

The CgA II assay helps to detect neuroendocrine tumours and is used to evaluate the success of cancer treatment. Furthermore, B·R·A·H·M·S CgA II KRYPTOR can be used for therapy monitoring of prostate cancer patients, especially those under androgen deprivation therapy. The assay provides fast and reproducible results.

Resources

The availability of products may vary in each country depending on local regulatory requirements.

Contact your local specialist for more details